Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) Financial Performance & Income Statement Overview
Explore the financials of Ocular Therapeutix, Inc. (OCUL), including yearly and quarterly data on income, cash flow, and balance sheets.
Ocular Therapeutix, Inc. (OCUL) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Ocular Therapeutix, Inc. OCUL financial performance.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $13.39M | $10.63M | $17.08M | $15.43M |
| Cost of Revenue | $1.94M | $1.26M | $1.23M | $1.56M |
| Gross Profit | $11.45M | $9.37M | $15.85M | $13.86M |
| Gross Profit Ratio | $0.85 | $0.88 | $0.93 | $0.90 |
| R&D Expenses | $51.08M | $42.86M | $40.99M | $37.05M |
| SG&A Expenses | $28.07M | $30.50M | $25.44M | $22.81M |
| Operating Expenses | $79.16M | $73.35M | $66.43M | $59.86M |
| Total Costs & Expenses | $81.10M | $74.61M | $67.66M | $61.42M |
| Interest Income | $3.46M | $3.83M | $4.67M | $5.65M |
| Interest Expense | -$3.02M | -$2.98M | $3.11M | $3.22M |
| Depreciation & Amortization | $0.00 | $3.12M | $951000.00 | $959000.00 |
| EBITDA | -$67.64M | -$63.92M | -$44.33M | -$32.31M |
| EBITDA Ratio | -$5.05 | -$6.01 | -$2.60 | -$2.09 |
| Operating Income | -$67.64M | -$63.92M | -$50.58M | -$46.00M |
| Operating Income Ratio | -$5.05 | -$6.01 | -$2.96 | -$2.98 |
| Other Income/Expenses (Net) | -$173000.00 | -$136000.00 | $2.19M | $9.51M |
| Income Before Tax | -$67.81M | -$64.05M | -$48.39M | -$36.49M |
| Income Before Tax Ratio | -$5.06 | -$6.02 | -$2.83 | -$2.37 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$67.81M | -$64.05M | -$48.39M | -$36.49M |
| Net Income Ratio | -$5.06 | -$6.02 | -$2.83 | -$2.37 |
| EPS | -$0.39 | -$0.38 | -$0.29 | -$0.22 |
| Diluted EPS | -$0.39 | -$0.38 | -$0.29 | -$0.22 |
| Weighted Avg Shares Outstanding | $172.59M | $169.40M | $168.02M | $166.99M |
| Weighted Avg Shares Outstanding (Diluted) | $172.59M | $169.40M | $168.02M | $166.99M |
Over the past four quarters, Ocular Therapeutix, Inc. demonstrated steady revenue growth, increasing from $15.43M in Q3 2024 to $13.39M in Q2 2025. Operating income reached -$67.64M in Q2 2025, maintaining a consistent -505% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$67.64M, reflecting operational efficiency. Net income dropped to -$67.81M, with EPS at -$0.39. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan